ONP-002

Oragenics has submitted an Investigator's Brochure for Phase II clinical trial of ONP-002, a novel intranasal neurosteroid targeting mild traumatic brain injury treatment in Australia.

Oragenics and BRAINBox Solutions have formed a strategic partnership to create the first comprehensive concussion management platform, combining diagnostic biomarkers with intranasal therapy ONP-002.

Oragenics is set to begin Phase II clinical trials in Australia for ONP-002, a treatment for mild traumatic brain injury, with first patient dosing aimed for late Q1 or early Q2 2025.

Oragenics Inc. terminated its President's employment agreement, as disclosed in a recent SEC filing, marking a significant leadership change.

Oragenics' ONP-002, a neurosteroid delivered intranasally, is advancing to Phase II clinical trials for treating moderate to severe concussions.